List of Excipients in Branded Drug OPDUALAG

Opdualag Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Opdualag is Bristol Myers Squibb’s fixed-dose intravenous combination of nivolumab, an anti-PD-1 antibody, and relatlimab, an anti-LAG-3 antibody. Its commercial differentiation depends on co-formulation stability, dual-antibody manufacturing control, administration convenience, and protection of the combination product rather than on novel excipients alone.

The principal excipient opportunity is not a simple copy of the approved formulation. It is the development of a stable, scalable, low-particulate formulation that preserves the activity of both antibodies, supports biosimilar or follow-on manufacturing, and reduces preparation and administration costs.

What is Opdualag and how is it formulated?

Opdualag is supplied as a sterile intravenous solution containing nivolumab and relatlimab at a fixed 3:1 active-ingredient concentration ratio by mass. The U.S. product is supplied in a single-dose vial for dilution and intravenous infusion. The labeled inactive ingredients include:

Component	Function in the formulation
L-histidine	Primary buffer
L-histidine hydrochloride monohydrate	Buffer capacity and pH control
Polysorbate 80	Surfactant that limits interfacial aggregation and adsorption
Pentetic acid	Chelating agent that can reduce metal-catalyzed degradation
Water for Injection	Injectable vehicle

The commercial product contains 240 mg of nivolumab and 80 mg of relatlimab per vial, according to the U.S. prescribing information. The formulation is administered intravenously after dilution in a compatible infusion solution. The product label controls storage, handling, dilution, and infusion conditions that directly affect excipient performance and protein stability. [1]

The excipient system is conventional for a monoclonal-antibody product. Its commercial value comes from its ability to stabilize two different antibodies in one liquid formulation, not from the individual ingredients being proprietary.

What excipients protect the Opdualag formulation?

The formulation has four principal technical functions: pH control, interfacial protection, metal-ion control, and maintenance of an injectable aqueous environment.

Histidine buffer

Histidine and histidine hydrochloride establish the formulation pH. Histidine is widely used in antibody formulations because it provides useful buffering near mildly acidic pH and generally has a favorable parenteral safety profile.

For Opdualag, the buffer must support both nivolumab and relatlimab. A pH that is acceptable for one antibody may accelerate aggregation, deamidation, oxidation, or loss of binding activity in the other. Dual-antibody optimization therefore creates a narrower formulation design space than a single-antibody product.

Polysorbate 80

Polysorbate 80 protects proteins from agitation, air-liquid interfaces, tubing contact, vial surfaces, and infusion handling. Its limitations include oxidation, hydrolysis, formation of subvisible particles, and interaction with container-closure components.

For a fixed combination product, polysorbate concentration must be sufficient to protect both antibodies without increasing degradation products or particulate burden. Supplier-to-supplier differences in peroxide content, fatty-acid distribution, and degradation profile can create a meaningful quality-control issue.

Pentetic acid

Pentetic acid, also known as DTPA, is a chelating agent. It can bind trace metal ions that catalyze oxidation or other degradation reactions. The excipient is used at low concentration, but its manufacturing value can be material because antibody products are sensitive to trace metals introduced through raw materials, equipment, process water, and packaging components.

Water for Injection

Water for Injection is the continuous phase and must meet compendial and manufacturing requirements. Its commercial importance is operational rather than differentiating. Control of bioburden, endotoxin, conductivity, and storage conditions remains essential for aseptic production.

How strong is the Opdualag excipient strategy?

The excipient strategy is technically credible but not inherently difficult to design around. Histidine, polysorbate 80, pentetic acid, and Water for Injection are established formulation components. A competitor would not generally need to use the same excipient concentrations or the same formulation process to develop a comparable product.

The more difficult technical barrier is achieving all of the following simultaneously:

1. Stable co-existence of nivolumab and relatlimab in one liquid formulation.
2. Retention of binding and biological activity for both antibodies.
3. Low visible and subvisible particle levels.
4. Acceptable aggregation and fragmentation profiles.
5. Stability under refrigerated storage and shipping excursions.
6. Compatibility with dilution, infusion bags, tubing, and administration equipment.
7. Consistent performance across commercial-scale batches.

This creates a moderate-to-high process-development barrier even where the excipient composition itself is not highly differentiated.

What formulation patents could protect Opdualag?

Formulation protection for Opdualag could target the combination product, the antibody ratio, excipient ranges, pH, concentration, storage conditions, container system, and manufacturing process.

Potential claim categories include:

Claim category	Commercial relevance
Dual-antibody liquid formulation	Can cover co-formulation of nivolumab and relatlimab in one container
Fixed concentration or ratio	Can restrict alternative presentations using the same active ingredients
Histidine and surfactant ranges	May protect selected stability windows rather than individual excipients
Chelator-containing formulation	Can address oxidation control and long-term stability
Container-closure system	Can cover vial materials, stopper composition, or adsorption-control measures
Dilution and administration method	May protect preparation or infusion conditions
Stability claims	Can cover defined storage periods, temperatures, or impurity limits
Manufacturing process	May address order of addition, mixing, filtration, hold time, or filling
Method of treatment	May cover combined PD-1 and LAG-3 blockade in specific patient populations

The strongest formulation claims generally connect composition to a measurable technical result, such as reduced aggregation, improved potency retention, lower particle formation, or extended shelf life. Claims limited to commonly used excipients at broad concentrations are more vulnerable to invalidity and design-around strategies.

Because Opdualag is a biologic licensed under a BLA, its U.S. exclusivity and patent position are not evaluated through the same Orange Book framework used for small-molecule drugs. Biologic reference products are tracked through FDA’s Purple Book, while relevant patents may be addressed through the Biologics Price Competition and Innovation Act patent-exchange process. [2,3]

When does Opdualag lose regulatory exclusivity?

Opdualag received FDA approval on March 18, 2022, for unresectable or metastatic melanoma in patients who had not received prior systemic therapy for advanced disease. [1]

As a reference biological product, it is eligible for 12 years of reference-product exclusivity under the U.S. biologics framework, subject to statutory provisions and any applicable pediatric exclusivity. The principal reference-product exclusivity date is therefore March 18, 2034, before consideration of any pediatric extension or separate patent barriers.

Regulatory exclusivity and patent expiration are different:

Protection	Practical effect
BLA approval	Establishes the reference biological product
12-year reference-product exclusivity	Restricts FDA approval of a biosimilar until the statutory period ends
Patent protection	Can delay or complicate launch beyond regulatory exclusivity
Method-of-use patents	May restrict labeled or patented clinical uses
Formulation patents	May affect specific co-formulations or presentations
Process patents	May increase manufacturing risk without necessarily blocking all products

No Orange Book listing should be expected for Opdualag because it is a biologic, not a conventional small-molecule drug. Patent expiry analysis must therefore be conducted through patent databases, FDA Purple Book information, USPTO records, litigation filings, and BMS disclosures rather than through an Orange Book entry. [2,4]

What biosimilar risks exist for Opdualag?

A biosimilar competitor would face a more complicated development program than a biosimilar to a single monoclonal antibody. The reference product contains two active antibodies with different targets, structures, binding characteristics, and degradation pathways.

A follow-on developer would likely need to establish:

• Analytical similarity for nivolumab and relatlimab separately.
• Similarity of the combined drug product.
• Comparable higher-order structure and post-translational modifications.
• Comparable binding to PD-1 and LAG-3 targets.
• Comparable functional activity for each antibody.
• Comparable impurity and aggregate profiles.
• Manufacturing consistency for a dual-antibody product.
• A scientifically justified clinical program under the 351(k) pathway.

The legal pathway for a dual-antibody product is less predictable than for a single-antibody biosimilar. FDA would evaluate whether the proposed product is biosimilar to the complete reference product, not merely to one active ingredient. The need to demonstrate similarity for two biologically active molecules increases analytical workload, reference-product sourcing requirements, and comparability risk.

A biosimilar could also pursue a different excipient system. It would not necessarily need to reproduce histidine, polysorbate 80, or pentetic acid if it can demonstrate comparable quality, safety, and effectiveness. The alternative formulation would need to avoid new immunogenicity, stability, administration, and compatibility concerns.

What commercial opportunities exist in Opdualag excipients?

Alternative surfactant systems

Polysorbate 80 is widely used but has recognized degradation and particulate risks. Commercial opportunities include higher-purity polysorbate 80, low-peroxide grades, controlled fatty-acid profiles, and alternative nonionic surfactants.

A supplier that can demonstrate lower oxidation, lower particle formation, or improved stability under shipping stress could compete for high-value biologic manufacturing contracts. Regulatory acceptance would depend on formulation-specific data and manufacturing controls.

Ready-to-use formulation platforms

Contract development and manufacturing organizations can offer dual-antibody formulation screening, accelerated stability testing, container-closure studies, and fill-finish services. The value proposition is shorter development time and reduced technical risk for biosimilar developers.

Low-volume administration systems

Opdualag’s fixed combination reduces the need to prepare two separate antibody products. Commercial opportunities include:

• Ready-to-dilute presentations.
• Closed-system transfer devices.
• Low-hold-up-volume infusion sets.
• Compatible bags and tubing.
• Automated pharmacy compounding systems.
• Prefilled or dual-chamber delivery systems, if technically and regulatorily viable.

Any new delivery format would require compatibility, sterility, extractables and leachables, dose accuracy, and stability data.

Container-closure materials

Protein adsorption and particulate formation can be influenced by vial glass, elastomer formulation, silicone oil, and stopper coatings. Suppliers with low-extractables stoppers, low-silicone systems, or improved protein-contact materials may capture value even without owning active-ingredient patents.

Manufacturing analytics

Dual-antibody products need robust assays that distinguish nivolumab from relatlimab and measure each antibody’s purity, aggregation, degradation, concentration, and biological activity. Analytical platforms are commercial opportunities in:

• Multi-attribute mass spectrometry.
• Capillary electrophoresis.
• Light-scattering particle analysis.
• Orthogonal aggregation assays.
• Dual-target binding assays.
• In-line or at-line concentration measurement.

How does Opdualag compare with separate Opdivo and relatlimab administration?

Attribute	Opdualag	Separate antibody products
Administration	One fixed-combination product	Two products and preparation steps
Dose flexibility	Lower, because the ratio is fixed	Higher, subject to labeling
Pharmacy workflow	Simplified	More complex
Formulation development	Requires dual-antibody compatibility	Each product optimized independently
Manufacturing	One co-formulated product	Separate production and supply chains
Commercial differentiation	Convenience and combination branding	Greater dosing flexibility
Biosimilar challenge	Dual-molecule comparability	Single-molecule pathways may be simpler

The fixed ratio is commercially useful because it simplifies administration and supports combination positioning. It also limits flexibility for patients who may require individualized dosing of one component.

What litigation and settlement risks affect Opdualag?

Potential disputes can arise over:

• Combination composition claims.
• Antibody sequence and epitope claims.
• Formulation and stability claims.
• Manufacturing and purification methods.
• Treatment methods involving PD-1 and LAG-3 blockade.
• Biosimilar patent-exchange disclosures.
• Declaratory judgment actions.
• Launch timing after regulatory approval.

Unlike small-molecule products, Opdualag does not have an Orange Book Paragraph IV pathway. A biosimilar sponsor may instead engage in the BPCIA patent-exchange process and related federal litigation. Settlement terms could govern launch timing, licensed formulation rights, manufacturing restrictions, or permitted indications.

The commercial risk is highest if a patent claim covers the fixed combination itself or an unavoidable manufacturing step. Risk is lower when claims cover optional excipients, narrow concentration ranges, or a particular container system that a competitor can avoid.

What is the commercial outlook for Opdualag excipients?

The largest near-term opportunities are in formulation-enabling materials and manufacturing services rather than commodity excipient supply. The highest-value suppliers will be those that can provide:

1. Consistent low-peroxide surfactants.
2. Dual-antibody stability data.
3. Low-particulate container systems.
4. Validated compatibility with infusion materials.
5. Regulatory documentation suitable for biosimilar development.
6. Scalable supply with tight lot-to-lot control.

Opdualag’s excipient composition is not an impenetrable barrier. Its defensibility comes from the integrated product platform: two antibodies, one liquid formulation, defined stability performance, sterile fill-finish, and a regulated administration process.

Key Takeaways

• Opdualag contains nivolumab and relatlimab in a fixed-dose intravenous combination.
• The principal excipients are histidine, histidine hydrochloride monohydrate, polysorbate 80, pentetic acid, and Water for Injection.
• The main technical challenge is stabilizing two antibodies in one liquid product.
• Excipient patents are more likely to protect ranges, combinations, stability outcomes, or manufacturing conditions than the individual excipients.
• Opdualag is a biologic and should be analyzed through the Purple Book and BPCIA framework, not the Orange Book Paragraph IV system.
• FDA approval occurred on March 18, 2022, creating a statutory reference-product exclusivity horizon extending to March 18, 2034, subject to applicable extensions.
• Commercial opportunities are strongest in low-peroxide surfactants, container-closure systems, analytical testing, fill-finish, infusion compatibility, and biosimilar formulation development.
• A biosimilar developer would face a dual-molecule analytical and manufacturing program, making Opdualag more complex than a single-antibody reference product.

FAQs

Can a biosimilar to Opdualag use a different excipient system?

Yes. A biosimilar developer may use different excipients if the product satisfies applicable quality, safety, efficacy, stability, and administration requirements. The alternative formulation must preserve the characteristics of both antibodies.

Is polysorbate 80 itself protected by Opdualag patents?

Polysorbate 80 is a widely used pharmaceutical excipient. Any enforceable protection would more likely concern a specific concentration range, formulation combination, stability result, or manufacturing process than the excipient alone.

Does Opdualag have an Orange Book patent listing?

No Orange Book listing should be expected because Opdualag is a biologic licensed under a BLA. Relevant patents are addressed through the biologics patent framework and conventional patent litigation channels.

Could Opdualag be converted into a subcutaneous formulation?

A subcutaneous version would require substantially higher concentration, injection-volume control, local tolerability assessment, device compatibility, and stability data. The fixed combination could create viscosity and dosing constraints that do not apply to the intravenous product.

Which excipient supplier has the strongest commercial position for Opdualag follow-on products?

Suppliers with validated low-peroxide surfactants, strong biologics documentation, dual-antibody formulation data, and reliable global supply have the strongest position. Commodity pricing alone is unlikely to determine supplier selection for a high-value combination biologic.

References

1. U.S. Food and Drug Administration. (2022). Opdualag (nivolumab and relatlimab-rmbw) prescribing information. Bristol Myers Squibb.

2. U.S. Food and Drug Administration. (2024). Purple Book: Lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations. https://purplebooksearch.fda.gov/

3. U.S. Food and Drug Administration. (2020). Questions and answers on biosimilar development and the BPCI Act: Guidance for industry. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.